FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006098261> ?p ?o ?g. }

• W2006098261 abstract "Acute kidney injury (AKI) is a devastating clinical condition strongly associated with increased morbidity and mortality in critically ill patients. Traditional methods of identifying kidney injury, through measurement of blood urea nitrogen and serum creatinine, are problematic in that they are slow to detect decreases in glomerular filtration rate (GFR) and are influenced by a variety of factors that are not related to GFR changes. Many genes are upregulated in the damaged kidney with the corresponding protein products appearing in plasma and urine. Some of these are candidate markers for more timely diagnosis of AKI. An ideal biomarker of kidney injury would be a substance that the kidney releases immediately in response to damage and that can be detected in the blood or urine without significant metabolism. In recent years, the the introduction of high-throughput omics technologies has led to identification of new biomarkers of renal damage with more favorable test characteristics than creatinine. Advances in this field of research are based on a more detailed understanding of the fundamental biological mechanisms involved in the renal damage progression, as well as on advances in genomic, transcriptomic, proteomic, and metabolomic research.The purpose of this special issue is to present original research and review articles that provide new insights into molecular pathology underlying the acute and chronic kidney injury and identify novel diagnostic and prognostic biomarkers for these clinical conditions.Many studies have explored the molecular events associated with the development of tubular atrophy and interstitial fibrosis induced by chronic urinary tract obstruction. Moreover it is well known that the recovery of renal function after relief of ureteral obstruction depends on several factors including the location and duration of the obstruction, whether it is complete or partial, time before relief, and the presence of infection [1]. In their article, G. Lucarelli et al. summarize the role of the emerging urinary biomarkers of obstructive nephropathy based on the current understanding of the pathophysiology of renal injury.Drug-induced nephrotoxicity plays an important role in the high prevalence and incidence of AKI, especially in neonatal intensive care units. In preterm newborns, one of the most important factors causing the pathogenesis and the progression of AKI is the interaction between the individual genetic code, the environment, the gestational age, and the disease. In this contest, M. Mussap et al. provide a broad overview of the current applications of metabolomics and novel biomarkers for assessing drug-induced toxic nephropathy and AKI in neonatology.Complement activation is an important mechanism of renal injury in different diseases and in particular in kidney damage associated with ischemia-reperfusion [2–5]. In this scenario, E. Rodriguez et al. showed that complement pathway was activated in AKI, regardless of the etiology of AKI, leading to the production of lytic complex C5b-C9. Moreover plasmatic membrane attack complex concentrations identified AKI patients at risk of developing serious outcomes like death during hospitalization or unrecovered renal function at time of hospital discharge.Nowadays the association of a calcineurin inhibitor (CNI) with mycophenolate mofetil (MMF) represents the backbone of solid-organ transplant immunosuppression. Although CNIs (cyclosporine A (CsA) and tacrolimus (FK506)) remain the most effective and widely used immunosuppressive agents in organ transplantation, their prolonged use may result in renal toxicity, renal dysfunction, and irreversible renal failure characterized by extensive tubulointerstitial fibrosis. To minimize the CNIs-associated nephrotoxicity, alternative protocols have been introduced especially with the increasing use of suboptimal donor organs [6–8]. One of these strategies includes the conversion from CsA to other drugs, especially sirolimus (SRL), an inhibitor of the mammalian target of rapamycin (mTOR). Using an experimental model to clarify the pathways of nephropathy evolution in a protocol of conversion from CsA to SRL, J. Sereno et al. demonstrated how conversion to SRL prevented CsA-induced renal damage evolution. Moreover these authors showed that prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF-β and IL-7 and kidney TGF-β and mTOR.These and other studies published in this special issue underline the need for new diagnostic and prognostic biomarkers. The discovery and validation of biomarkers for AKI will improve the early diagnosis of tubular injury, thereby facilitating timely therapeutic intervention. Novel, sensitive biomarkers should also help to differentiate between etiologies of AKI, predict the severity of renal damage, and provide a tool for differentiating between patients who would benefit from early initiation of renal replacement therapy and those from whom support should be withheld or withdrawn.Pasquale DitonnoCees van KootenLoreto GesualdoGiuseppe GrandalianoGiuseppe Lucarelli" @default.
• W2006098261 created "2016-06-24" @default.
• W2006098261 creator A5001391327 @default.
• W2006098261 creator A5003929233 @default.
• W2006098261 creator A5024426681 @default.
• W2006098261 creator A5045412958 @default.
• W2006098261 creator A5069641539 @default.
• W2006098261 date "2014-01-01" @default.
• W2006098261 modified "2023-09-25" @default.
• W2006098261 title "Emerging Biomarkers in Renal Damage" @default.
• W2006098261 cites W1974854558 @default.
• W2006098261 cites W2004990960 @default.
• W2006098261 cites W2014060025 @default.
• W2006098261 cites W2055022002 @default.
• W2006098261 cites W2063704518 @default.
• W2006098261 cites W2084280920 @default.
• W2006098261 cites W2096895041 @default.
• W2006098261 cites W2104346652 @default.
• W2006098261 doi "https://doi.org/10.1155/2014/893068" @default.
• W2006098261 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4168029" @default.
• W2006098261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25276826" @default.
• W2006098261 hasPublicationYear "2014" @default.
• W2006098261 type Work @default.
• W2006098261 sameAs 2006098261 @default.
• W2006098261 citedByCount "0" @default.
• W2006098261 crossrefType "journal-article" @default.
• W2006098261 hasAuthorship W2006098261A5001391327 @default.
• W2006098261 hasAuthorship W2006098261A5003929233 @default.
• W2006098261 hasAuthorship W2006098261A5024426681 @default.
• W2006098261 hasAuthorship W2006098261A5045412958 @default.
• W2006098261 hasAuthorship W2006098261A5069641539 @default.
• W2006098261 hasBestOaLocation W20060982611 @default.
• W2006098261 hasConcept C126322002 @default.
• W2006098261 hasConcept C142724271 @default.
• W2006098261 hasConcept C159641895 @default.
• W2006098261 hasConcept C177713679 @default.
• W2006098261 hasConcept C2778176769 @default.
• W2006098261 hasConcept C2778653478 @default.
• W2006098261 hasConcept C2780091579 @default.
• W2006098261 hasConcept C2780306776 @default.
• W2006098261 hasConcept C2780472472 @default.
• W2006098261 hasConcept C2781197716 @default.
• W2006098261 hasConcept C54847362 @default.
• W2006098261 hasConcept C55493867 @default.
• W2006098261 hasConcept C60644358 @default.
• W2006098261 hasConcept C71924100 @default.
• W2006098261 hasConcept C77411442 @default.
• W2006098261 hasConcept C86803240 @default.
• W2006098261 hasConceptScore W2006098261C126322002 @default.
• W2006098261 hasConceptScore W2006098261C142724271 @default.
• W2006098261 hasConceptScore W2006098261C159641895 @default.
• W2006098261 hasConceptScore W2006098261C177713679 @default.
• W2006098261 hasConceptScore W2006098261C2778176769 @default.
• W2006098261 hasConceptScore W2006098261C2778653478 @default.
• W2006098261 hasConceptScore W2006098261C2780091579 @default.
• W2006098261 hasConceptScore W2006098261C2780306776 @default.
• W2006098261 hasConceptScore W2006098261C2780472472 @default.
• W2006098261 hasConceptScore W2006098261C2781197716 @default.
• W2006098261 hasConceptScore W2006098261C54847362 @default.
• W2006098261 hasConceptScore W2006098261C55493867 @default.
• W2006098261 hasConceptScore W2006098261C60644358 @default.
• W2006098261 hasConceptScore W2006098261C71924100 @default.
• W2006098261 hasConceptScore W2006098261C77411442 @default.
• W2006098261 hasConceptScore W2006098261C86803240 @default.
• W2006098261 hasLocation W20060982611 @default.
• W2006098261 hasLocation W20060982612 @default.
• W2006098261 hasLocation W20060982613 @default.
• W2006098261 hasLocation W20060982614 @default.
• W2006098261 hasOpenAccess W2006098261 @default.
• W2006098261 hasPrimaryLocation W20060982611 @default.
• W2006098261 hasRelatedWork W1966166130 @default.
• W2006098261 hasRelatedWork W1982875844 @default.
• W2006098261 hasRelatedWork W2000047885 @default.
• W2006098261 hasRelatedWork W2070087000 @default.
• W2006098261 hasRelatedWork W2092337821 @default.
• W2006098261 hasRelatedWork W2121846959 @default.
• W2006098261 hasRelatedWork W2144387792 @default.
• W2006098261 hasRelatedWork W2152247153 @default.
• W2006098261 hasRelatedWork W2168530538 @default.
• W2006098261 hasRelatedWork W2351232173 @default.
• W2006098261 hasRelatedWork W2514465097 @default.
• W2006098261 hasRelatedWork W2754225782 @default.
• W2006098261 hasRelatedWork W2772170993 @default.
• W2006098261 hasRelatedWork W2886678399 @default.
• W2006098261 hasRelatedWork W2895652991 @default.
• W2006098261 hasRelatedWork W2978374834 @default.
• W2006098261 hasRelatedWork W3080758811 @default.
• W2006098261 hasRelatedWork W3128812093 @default.
• W2006098261 hasRelatedWork W3135375687 @default.
• W2006098261 hasRelatedWork W3149972328 @default.
• W2006098261 isParatext "false" @default.
• W2006098261 isRetracted "false" @default.
• W2006098261 magId "2006098261" @default.
• W2006098261 workType "article" @default.